Natick healthcare startup Naveris announced the closure of its Series A financing round Tuesday, noting it has raised $19 million since the company was founded.
The company is focused on improving patient care through early detection of virus-related cancers, according to a release from the company. Naveris applies proprietary technology to detect cancer using genetic fingerprints from circulating tumor DNA.
Naveris’ lead product, NavDx, applies technology to enable detection of HPV-related cancer.
Gurnet Point Capital, a Cambridge private investment fund focused in the healthcare and life sciences sector, led the financing round.The funds will be used to generate more data about Naveris’ treatments as well as for continued product development.
